• The AGIR project (Antibiotics against Resistant Infectious Germs), carried out by the DEINOVE group and the Charles Viollette Institute, aims to identify novel antibiotic structures from rare bacterial strains by developing new collection, culture, screening, optimization, and evaluation methods.
  • The ‘Investments for the Future’ Program supports the AGIR project by financing €14.6 million over five years.
  • This support demonstrates the French government's commitment to fighting resistance to antibiotics, which is a major health issue on a global scale.

DEINOVE (Alternext Paris: ALDEI), a biotech company that discovers, develops, and produces high-value compounds from rare bacteria, notably from the Deinococcus genus, announces that its AGIR project, carried out jointly with its subsidiary DEINOBIOTICS and the Charles Viollette Institute (ICV, Lille University 1), was selected by the ‘Investments for the Future’ Program, led by the General Investment Commission (CGI) and operated by Bpifrance, within the framework of the call for projects "Structural R&D Projects for Competitiveness".

As such, the AGIR project will be financed to a level of €14.6 million, for a total budget estimated at €25 million. Grants making up almost half of the funding will be spread over the five-year program duration. The DEINOVE Group will receive €10.4 million while the Charles Viollette Institute will receive €4.2 million.

Aïcha DOUHOU, Life Sciences sector Manager at BPIFrance Innovation, commented: "We are very pleased to support DEINOVE in its innovative approach around the discovery of new antibiotics. This should accelerate the development of solutions to address infectious diseases that are developing more and more rapidly at a global level."

Emmanuel PETIOT, CEO of DEINOVE added: "Our approach is totally original in the world of pharmacy because it combines the molecular biology expertise of DEINOVE with the experience in medicinal chemistry and enzymatic engineering of the DEINOBIOTICS teams and of the CHARLES VIOLLETTE INSTITUTE (CVI). This funding will accelerate the growth of our platform, enrich our portfolio of molecules and thus contribute to the development of treatments responding to the medical emergency. The support of the ‘Investments for the Future’ Program marks both the recognition of our innovative technological approach and the commitment of public authorities to the discovery of new antibiotics that will help stop the phenomena of microbial resistance."

Pascal DHULSTER, Director of the CVI and Dominique Le Beller, CEO of DEINOBIOTICS, added: "We have built this platform step by step with the expertise of our teams in infectiology, medicinal chemistry, microbiology, fermentation, and analytical engineering. The synergies between the three partners, the complementarity and the creativity of our teams are essential assets for the success of the AGIR project. With this funding, we aim to be at the forefront of the world in the discovery and development of new antibiotic structures."

Bpifrance is the managing operator for research and development projects structuring competitiveness under the ‘Investments for the Future’ Program led by the General Investment Commission. The goal of these projects is to frame and organize industry sectors or to generate new ones. They aim to strengthen the positions of French businesses in key markets by providing funding for ambitious programs. More broadly they aim to enhance the economic standing of a network of enterprises, by building or consolidating sustainable collaborative relationships between manufacturing, service industries and research organizations